{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:39:07Z","timestamp":1782538747274,"version":"3.54.5"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-031605"],"award-info":[{"award-number":["INV-031605"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010648","name":"Polio Research Council","doi-asserted-by":"publisher","award":["2022\/1217583\u20130"],"award-info":[{"award-number":["2022\/1217583\u20130"]}],"id":[{"id":"10.13039\/100010648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010648","name":"Polio Research Council","doi-asserted-by":"publisher","award":["MR\/X020258\/1"],"award-info":[{"award-number":["MR\/X020258\/1"]}],"id":[{"id":"10.13039\/100010648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Between 2016 and 2023, 3248 cases of circulating vaccine-derived type 2 poliomyelitis (cVDPV2) were reported globally and supplementary immunization activities (SIAs) with monovalent type 2 oral poliovirus vaccine (mOPV2) and novel type 2 oral poliovirus vaccine (nOPV2) targeted an estimated 356 and 525 million children, respectively. This analysis estimates the community-level impact of nOPV2 relative to mOPV2 SIAs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We fitted interrupted time-series regressions to surveillance data between January 2016 and November 2023 to estimate the impact of nOPV2 and mOPV2 SIAs on cVDPV2 poliomyelitis incidence and prevalence in environmental surveillance across 37 countries, directly comparing the impact of SIAs in 13 countries where both vaccines were used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We did not find any statistically significant differences between nOPV2 and mOPV2 SIA impact except for in the Democratic Republic of Congo (DRC), where nOPV2 SIAs had lower impact (adjusted relative risk [aRR] for cVDPV2 poliomyelitis incidence per nOPV2 SIA, 0.505; 95% confidence interval [CI], .409\u2013.623) compared to mOPV2 (aRR, 0.193; 95% CI, .137\u2013.272); P value for difference in RRs = 3e-6.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We find variation in OPV2 SIA impacts globally, with greater certainty about Nigeria and DRC, where large outbreaks provided an opportunity to assess impact at scale. In most countries, we find no significant difference between nOPV2 and mOPV2 SIA impact. We are unable to identify the reason for the significant difference in DRC, which could include differential SIA coverage, timing, vaccine effectiveness, or outbreak dynamics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae614","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T14:01:52Z","timestamp":1738072912000},"page":"e446-e455","source":"Crossref","is-referenced-by-count":3,"title":["Global Impact of Mass Vaccination Campaigns on Circulating Type 2 Vaccine-Derived Poliovirus Outbreaks: An Interrupted Time-Series Analysis"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-3627","authenticated-orcid":false,"given":"Laura V","family":"Cooper","sequence":"first","affiliation":[{"name":"School of Public Health, Medical Research Council Centre for Global Infectious Disease Analysis, Imperial College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-2001","authenticated-orcid":false,"given":"Ananda S","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"Bill and Melinda Gates Foundation , Polio Team, Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6067-4507","authenticated-orcid":false,"given":"Nicholas C","family":"Grassly","sequence":"additional","affiliation":[{"name":"School of Public Health, Medical Research Council Centre for Global Infectious Disease Analysis, Imperial College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-5334","authenticated-orcid":false,"given":"Elizabeth J","family":"Gray","sequence":"additional","affiliation":[{"name":"School of Public Health, Medical Research Council Centre for Global Infectious Disease Analysis, Imperial College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6242-7796","authenticated-orcid":false,"given":"Arie","family":"Voorman","sequence":"additional","affiliation":[{"name":"Bill and Melinda Gates Foundation , Polio Team, Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Zipursky","sequence":"additional","affiliation":[{"name":"Bill and Melinda Gates Foundation , Polio Team, Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3977-1318","authenticated-orcid":false,"given":"Isobel M","family":"Blake","sequence":"additional","affiliation":[{"name":"School of Public Health, Medical Research Council Centre for Global Infectious Disease Analysis, Imperial College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"2025022016352423800_jiae614-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","article-title":"Mucosal immunity to poliovirus","volume":"15","author":"Connor","year":"2022","journal-title":"Mucosal Immunol"},{"key":"2025022016352423800_jiae614-B2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"key":"2025022016352423800_jiae614-B3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiad004","article-title":"The origins and risk factors for serotype-2 vaccine-derived poliovirus emergences in Africa during 2016\u20132019","volume":"228","author":"Gray","year":"2023","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"2025022016352423800_jiae614-B4","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J Infect Dis"},{"key":"2025022016352423800_jiae614-B5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"key":"2025022016352423800_jiae614-B6","author":"World Health Organization"},{"key":"2025022016352423800_jiae614-B7","doi-asserted-by":"crossref","first-page":"e0002920","DOI":"10.1371\/journal.pgph.0002920","article-title":"One billion doses and WHO prequalification of nOPV2: implications for the global polio situation and beyond","volume":"4","author":"Bandyopadhyay","year":"2024","journal-title":"PLOS Glob Public Health"},{"key":"2025022016352423800_jiae614-B8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","article-title":"Engineering the live-attenuated polio vaccine to prevent reversion to virulence","volume":"27","author":"Yeh","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2025022016352423800_jiae614-B9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials","volume":"397","author":"S\u00e1ez-Llorens","year":"2021","journal-title":"Lancet"},{"key":"2025022016352423800_jiae614-B10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(22)02397-2","article-title":"Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial","volume":"401","author":"Zaman","year":"2023","journal-title":"Lancet"},{"key":"2025022016352423800_jiae614-B11","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(23)02844-1","article-title":"Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to &lt;5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in the Gambia: a phase 3, double-blind, randomised controlled trial","volume":"403","author":"Ochoge","year":"2024","journal-title":"Lancet"},{"key":"2025022016352423800_jiae614-B12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0140-6736(24)00053-9","article-title":"First Africa-based clinical trial for novel type 2 oral poliovirus vaccine","volume":"403","author":"Cooper","year":"2024","journal-title":"Lancet"},{"key":"2025022016352423800_jiae614-B13","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/clinids\/13.5.926","article-title":"Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review","volume":"13","author":"Patriarca","year":"1991","journal-title":"Rev Infect Dis"},{"key":"2025022016352423800_jiae614-B14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12916-016-0600-z","article-title":"Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria","volume":"14","author":"Upfill-Brown","year":"2016","journal-title":"BMC Med"},{"key":"2025022016352423800_jiae614-B15","author":"Global Polio Eradication Initiative"},{"key":"2025022016352423800_jiae614-B16","author":"Global Polio Eradication Initiative"},{"key":"2025022016352423800_jiae614-B17","author":"World Health Organization Department of Immunization Vaccines and Biologicals"},{"key":"2025022016352423800_jiae614-B18","author":"Global Polio Eradication Initiative"},{"issue":"Suppl 1","key":"2025022016352423800_jiae614-B19","doi-asserted-by":"crossref","first-page":"A85","DOI":"10.1016\/j.vaccine.2022.03.013","article-title":"Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine","volume":"41","author":"Voorman","year":"2023","journal-title":"Vaccine"},{"key":"2025022016352423800_jiae614-B20","author":"Institute for Disease Modelling"},{"key":"2025022016352423800_jiae614-B21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/infdis\/jiab518","article-title":"Time taken to detect and respond to polio outbreaks in Africa and the potential impact of direct molecular detection and nanopore sequencing","volume":"226","author":"Shaw","year":"2022","journal-title":"J Infect Dis"},{"key":"2025022016352423800_jiae614-B22"},{"key":"2025022016352423800_jiae614-B23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1478-7954-11-11","article-title":"Millennium development health metrics: where do Africa's children and women of childbearing age live?","volume":"11","author":"Tatem","year":"2013","journal-title":"Popul Health Metr"},{"key":"2025022016352423800_jiae614-B24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2288-14-122","article-title":"Conditional Poisson models: a flexible alternative to conditional logistic case cross-over analysis","volume":"14","author":"Armstrong","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025022016352423800_jiae614-B25","author":"Turner"},{"key":"2025022016352423800_jiae614-B26","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2022"},{"key":"2025022016352423800_jiae614-B27","volume-title":"Modern applied statistics with S-PLUS","author":"Venables","year":"2013"},{"key":"2025022016352423800_jiae614-B28","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(23)00139-1","article-title":"Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial","volume":"23","author":"Wilkinson","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025022016352423800_jiae614-B29","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.15585\/mmwr.mm7238a4","article-title":"Notes from the field: circulating vaccine-derived poliovirus type 2 emergences linked to novel oral poliovirus vaccine type 2 use\u2014six African countries, 2021\u20132023","volume":"72","author":"Davlantes","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025022016352423800_jiae614-B30","doi-asserted-by":"crossref","first-page":"e1005728","DOI":"10.1371\/journal.ppat.1005728","article-title":"Preventing vaccine-derived poliovirus emergence during the polio endgame","volume":"12","author":"Pons-Salort","year":"2016","journal-title":"PLOS Pathog"},{"key":"2025022016352423800_jiae614-B31","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/aje\/kwq320","article-title":"From emergence to eradication: the epidemiology of poliomyelitis deconstructed.","volume":"172","author":"Nathanson","year":"2010","journal-title":"Am J Epidemiol"},{"key":"2025022016352423800_jiae614-B32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/infdis\/jiad222","article-title":"Evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria","volume":"229","author":"Voorman","year":"2023","journal-title":"J Infect Dis"},{"key":"2025022016352423800_jiae614-B33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3201\/eid2302.161210","article-title":"Estimated effect of inactivated poliovirus vaccine campaigns, Nigeria and Pakistan, January 2014-April 2016","volume":"23","author":"Shirreff","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2025022016352423800_jiae614-B34","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3201\/eid2411.180050","article-title":"Effect of inactivated poliovirus vaccine campaigns, Pakistan, 2014\u20132017","volume":"24","author":"Grassly","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2025022016352423800_jiae614-B35","volume-title":"Standard operating procedures: responding to a poliovirus event or outbreak, version 4.1","author":"Global Polio Eradication Initiative","year":"2022"},{"key":"2025022016352423800_jiae614-B36","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2666-5247(22)00254-3","article-title":"Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials","volume":"3","author":"Wahid","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025022016352423800_jiae614-B37","doi-asserted-by":"crossref","first-page":"786","DOI":"10.15585\/mmwr.mm7124a2","article-title":"Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing\u2014worldwide, March\u2013October 2021","volume":"71","author":"Martin","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae614\/61616826\/jiae614.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/2\/e446\/61616826\/jiae614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/2\/e446\/61616826\/jiae614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:36:55Z","timestamp":1740069415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/2\/e446\/7950519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae614","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2025,1,28]]}}}